When concentration were compared to IC50 values derived in vitro, clinical trial simulations predicted that at full adherence BRCA mutation carriers reached the IC50 for PARP1 inhibition, but tumor concentrations did not reach the IC50 in the cell proliferation assays as threshold of response patient simulations (n = 1000, Fig. 4d). The gene discussed is PARP1; the disease is neoplasm.